ABACAVIR, LAMIVUDINE AND ZIDOVUDINE

NDC product · U.S. Food and Drug Administration (openFDA) · United States

  • Product NDC 68180-286
  • Application number ANDA202912
  • SPL ID e180b9ff-1e7c-422a-9fe7-afd39eee3e4e
  • SPL set ID f5f7c0d9-a247-4308-8269-32accc490ea6
  • UNII 2T8Q726O95
  • UNII 4B9XT59T7S
  • UNII J220T4J9Q2
  • RxCUI 307650

What the source publishes

Labeler
Lupin Pharmaceuticals, Inc.
Active ingredients
ABACAVIR , LAMIVUDINE AND ZIDOVUDINE
Form
TABLET
Routes
ORAL
Administrative status
present-in-source-snapshot
Marketing status
ANDA
Product type
HUMAN PRESCRIPTION DRUG
Prescription
Prescription or restricted

Names this record is found by

Complete source data
us:fda:ndc:68180-286_e180b9ff-1e7c-422a-9fe7-afd39eee3e4e
{
  "name": "ABACAVIR, LAMIVUDINE AND ZIDOVUDINE",
  "splId": "e180b9ff-1e7c-422a-9fe7-afd39eee3e4e",
  "labels": [
    {
      "setId": "f5f7c0d9-a247-4308-8269-32accc490ea6",
      "labelUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5f7c0d9-a247-4308-8269-32accc490ea6",
      "labelPdfUrl": "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=f5f7c0d9-a247-4308-8269-32accc490ea6"
    }
  ],
  "routes": [
    "ORAL"
  ],
  "labeler": "Lupin Pharmaceuticals, Inc.",
  "finished": true,
  "packaging": [],
  "productId": "68180-286_e180b9ff-1e7c-422a-9fe7-afd39eee3e4e",
  "useDomain": "unknown",
  "dosageForm": "TABLET",
  "productNdc": "68180-286",
  "deaSchedule": null,
  "genericName": "ABACAVIR , LAMIVUDINE AND ZIDOVUDINE",
  "productType": "HUMAN PRESCRIPTION DRUG",
  "listingStatus": "present-in-source-snapshot",
  "targetSpecies": [],
  "approvalStatus": "not-established-by-ndc-listing",
  "labelAssociation": "openFDA-harmonized-set-ids; not a product-level approval match",
  "marketingEndDate": null,
  "activeIngredients": [
    {
      "name": "LAMIVUDINE",
      "strength": "150 mg/1"
    },
    {
      "name": "ZIDOVUDINE",
      "strength": "300 mg/1"
    },
    {
      "name": "ABACAVIR SULFATE",
      "strength": "300 mg/1"
    }
  ],
  "applicationNumber": "ANDA202912",
  "marketingCategory": "ANDA",
  "stateRestrictions": {
    "status": "not-collected",
    "observations": []
  },
  "useDomainEvidence": {
    "basis": "unreviewed",
    "field": null,
    "value": null,
    "version": 1,
    "sourceId": "us.fda.ndc"
  },
  "marketingStartDate": "20131217",
  "targetSpeciesStatus": "not-reported",
  "prescriptionCategory": "prescription-or-restricted",
  "harmonizedIdentifiers": {
    "nui": [
      "N0000175656",
      "N0000175462",
      "N0000009947"
    ],
    "unii": [
      "2T8Q726O95",
      "4B9XT59T7S",
      "J220T4J9Q2"
    ],
    "rxcui": [
      "307650"
    ],
    "spl_set_id": [
      "f5f7c0d9-a247-4308-8269-32accc490ea6"
    ],
    "pharm_class_epc": [
      "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]",
      "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
      "Nucleoside Reverse Transcriptase Inhibitors [MoA]"
    ],
    "manufacturer_name": [
      "Lupin Pharmaceuticals, Inc."
    ],
    "is_original_packager": [
      true
    ]
  },
  "listingExpirationDate": "20271231"
}

Read this record from your own software

The same record, with every field and its provenance, is one request away. An API key is free and works immediately.

GET /v1/drugs/record
curl -G "https://api.medifontis.com/v1/drugs/record" \
  -H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
  --data-urlencode "country=us" \
  --data-urlencode "sourceId=us.fda.ndc" \
  --data-urlencode "id=us:fda:ndc:68180-286_e180b9ff-1e7c-422a-9fe7-afd39eee3e4e"